BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...
Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK inhibitor to a 12% reduction in the risk of disability progression compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results